Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Clinical trial NCT00684411 · COMPLETED

Trial details

NCT number: NCT00684411
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

T Cell Non-Hodgkin Lymphoma

Start date: 2008-06-01
Primary completion: 2013-10-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.